

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

SECRETARY OF THE SENATE

01 AUG 14 PM 12:

1. Registrant Name <b>Swidler Berlin Shereff Friedman, LLP</b>			
2. Address <input type="checkbox"/> Check if different than previously reported <b>3000 K Street, N.W., Suite 300</b>			
3. Principal Place of Business (if different from line 2) City: <b>Washington</b> State/Zip (or Country) <b>D.C. 20007</b>			
4. Contact Name <b>Lester Hyman</b>	Telephone <b>(202) 424-7500</b>	E-mail (optional)	5. Senate ID <b>37460-56</b>
7. Client Name <input type="checkbox"/> Self <b>Aventis Pharmaceutical, Inc.</b>	6. House <b>3141905</b>		

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date \_\_\_\_\_ 11. No Lobbying ☐

## INCOME OR EXPENSES - Complete Either Line 12 OR 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐

\$10,000 or more ☒  $\Rightarrow$  \$ 20,000  
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000 ☐

\$10,000 or more ☐  $\Rightarrow$  \$ \_\_\_\_\_  
Expenses (nearest \$20,000)

**14. REPORTING METHOD.** Check box to indicate accounting method. See instructions for description

☐ **Method A.** Reporting amounts using LDA del

☐ **Method B.** Reporting amounts under section 162(e) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title Lester Hyman, Partner

LD-2 (REV. 6/98)

*[Redacted Signature]*

Registrant Name Swidler Berlin Shereff Friedman, LLP Client Name Aventis Pharmaceutical, Inc

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Patent legislation affecting the introduction of drugs into the market.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Brian Fitzgerald	
Keith Cole	
Barry Drenfeld	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature  Date 8/2/01

Printed Name and Title Lester Hyman, Partner

